310 related articles for article (PubMed ID: 18489056)
1. Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Steinhoff M; Beyer M; Roewert-Huber J; Lukowsky A; Assaf C; Sterry W
J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S88-91. PubMed ID: 18489056
[TBL] [Abstract][Full Text] [Related]
2. Juvenile mycosis fungoides treated with bexarotene and PUVA.
Rodríguez-Vázquez M; García-Arpa M; González-García J
Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
[TBL] [Abstract][Full Text] [Related]
3. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
4. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
5. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
7. [Granulomatous mycosis fungoides histologically simulating cutaneous sarcoidosis].
Maillard H; Croué A; François S; Verret JL
Ann Dermatol Venereol; 1998 Dec; 125(12):912-5. PubMed ID: 9922868
[TBL] [Abstract][Full Text] [Related]
8. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
9. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
[TBL] [Abstract][Full Text] [Related]
10. Development of multiple basal cell carcinomas in mycosis fungoides treated with oral bexarotene.
Calzavara-Pinton P; Leali C; Venturini M; Sala R; Zane C
Eur J Dermatol; 2007; 17(4):341-2. PubMed ID: 17540649
[No Abstract] [Full Text] [Related]
11. Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene.
Mehlmauer MA
Cutis; 2004 Jun; 73(6):417-20. PubMed ID: 15224787
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
13. Poikilodermatous mycosis fungoides.
Farley-Loftus R; Mandal R; Latkowski JA
Dermatol Online J; 2010 Nov; 16(11):8. PubMed ID: 21163159
[TBL] [Abstract][Full Text] [Related]
14. Development of a prominent granulomatous eruption after interferon-gamma therapy in a patient with mycosis fungoides.
Haruyama S; Sugita K; Kawakami C; Nakamura M; Tokura Y
Acta Derm Venereol; 2010 Mar; 90(2):190-1. PubMed ID: 20169308
[No Abstract] [Full Text] [Related]
15. Retinoid dermatitis mimicking progression in mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Group.
Molin L; Thomsen K; Volden G; Lange Wantzin G
Acta Derm Venereol; 1985; 65(1):69-71. PubMed ID: 2578710
[TBL] [Abstract][Full Text] [Related]
16. Granulomatous mycosis fungoides. A 14-year follow-up of a case.
Flaxman BA; Koumans JA; Ackerman AB
Am J Dermatopathol; 1983 Apr; 5(2):145-51. PubMed ID: 6881480
[TBL] [Abstract][Full Text] [Related]
17. Sézary syndrome associated with granulomatous lesions during treatment with bexarotene.
Ruiz-de-Casas A; Carrizosa-Esquivel A; Herrera-Saval A; Rios-Martín JJ; Camacho F
Br J Dermatol; 2006 Feb; 154(2):372-4. PubMed ID: 16433814
[TBL] [Abstract][Full Text] [Related]
18. Long-term control of mycosis fungoides of the hands with topical bexarotene.
Lain T; Talpur R; Duvic M
Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
[TBL] [Abstract][Full Text] [Related]
19. Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides.
Michaelis S; Cozzio A; Kempf W; Graf P; Burg G; Dummer R
Dermatology; 2004; 209(1):72-4. PubMed ID: 15237276
[No Abstract] [Full Text] [Related]
20. Foreign-body-associated granulomatous slack skin in folliculotropic mycosis fungoides of childhood.
Tronnier M
J Cutan Pathol; 2009 May; 36(5):578-81. PubMed ID: 19476528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
